Exscientia

Exscientia

Exscientia

A leading British drug design company whose innovative AI (Artificial Intelligence) technologies deliver high quality, small molecule drugs with unrivalled productivity.
Type
B2b
Founded
2012
Raised
$251M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$225,000,000
Venture capital (Series D) - 2021
BlackRock Casdin Capital Farallon Capital Management +8
$26,000,000
Venture capital (Series B) - 2019
GT Healthcare Celgene Corporation Evotec AG
Team Size
1–10
Employees
MedCity News

Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia

MedCity News

AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D

neurons.AI

EQRx puts Exscientia’s AI on drug discovery duty to develop low-cost cancer drugs

neurons.AI

Exscientia Enters Binding Agreement to Acquire Allcyte

neurons.AI

British AI drug discovery startup Exscientia buys Austrian cancer cell screening company

Pulse 2.0

Exscientia Secures Investment Of Up To $525 Million

$225,000,000 Venture capital (Series D)
neurons.AI , neurons.AI

AI Drug Developer Exscientia Closes $525M in Financing

neurons.AI

Exscientia starts trials of first AI-derived cancer immunotherapy

UKTN (UK Tech News)

Exscientia raises $60m Series C

the home of AI info

SRI International and Exscientia Enter Collaboration to Accelerate Drug Discovery Through …

the home of AI info

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular ...

MedCity News

AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate

$26,000,000 Venture capital (Series B)
PE HUB , FinSMEs

Exscientia lands $26 mln Series B